Hematopoietic/Lymphoid Cancer Clinical Trial
Official title:
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
RATIONALE: A stress management intervention may be more effective than usual care in
improving quality of life in caregivers of patients undergoing bone marrow transplant.
PURPOSE: This randomized phase III trial is studying a stress management intervention for
caregivers of patients undergoing bone marrow transplant.
Specific Aims
- Further validate a unique saliva collection device in a randomized controlled study of
a psychoeducation, paced respiration, and relaxation (PEPRR) intervention for
caregivers of patients undergoing bone marrow transplantation.
- Evaluate the suitability of paced respiratory training using RESPeRATE™ for these
caregivers.
- Determine the efficacy of a PEPRR intervention on behavioral (stress level, mood and
overall health) and physiological (neuroendocrine function, immune function, and sleep)
outcomes of these caregivers.
OUTLINE: Caregivers are randomized to 1 of 2 groups.
- Group I (treatment as usual [TAU]): Caregivers and patients attend a 2-hour orientation
class that provides an overview of the transplant process, information regarding
financial issues and resources that may be available to the patient and caregiver, a
review of caregiver duties, dietary restrictions post-transplantation, a brief
introduction to stress and stress management, and hands-on training of how to care for
a central venous catheter. Patients also receive information in the form of a written
manual that provides in-depth information about transplant, including how the
transplant works, what to expect, caregiver duties, graft-vs-host disease, and when to
contact medical staff for assistance. A voluntary 1-hour weekly caregiver support group
is offered on the inpatient BMT unit.
- Group II (psychoeducation, paced respiration, and relaxation [PEPRR]): Caregivers and
patients attend a 2-hour orientation class identical to group I. Caregivers also
participate in the PEPRR intervention comprising an individualized stress management
component and educational component that addresses the psychosocial needs of the
caregivers. It also provides self-care and adaptive coping skills. The stress
management component addresses caregivers' perception of potential stressors (primary
appraisal); perceived ability to control or manage the stressor (secondary appraisal);
ability to exert control and cope with the stressor (coping effort); and ongoing
evaluation of the stressor and their perceived ability of managing the stressor
(reappraisal) and applies coping strategies such as relaxation, prioritizing, goal
setting, pacing, and communicating needs. The PEPRR intervention consists of 8 sessions
(4 weekly 60-minute sessions followed by 4 biweekly 60-minute sessions) that cover the
100-day period of caregiving post-transplantation. Caregivers also undergo paced
respiratory (RESPeRATE™) training for 15 minutes once daily over 12 weeks that measures
caregiver adherence and compliance to the relaxation program.
Caregivers and patients undergo psychosocial assessments at approximately 1-3 months prior
to randomization and transplantation and again at 1, 3, 6, and 12 months after
transplantation. Caregivers also complete questionnaires to assess their stress (PSS, CRA,
and IES), mood (POMS, CES-D, and STAI), sleep (PSQI), and health (SF-36).
Caregivers undergo blood and saliva sample collection at baseline and periodically during
study for biomarker analysis (e.g., neuroendocrine and immune markers). Caregivers wear an
activity watch (actimeter) during each saliva sample collection period.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02903810 -
Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00710632 -
Screening to Predict Weight Loss in Patients With Cancer
|
N/A | |
Active, not recruiting |
NCT01056614 -
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
|
Phase 2 | |
Terminated |
NCT00089089 -
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT03654404 -
A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients
|
N/A | |
Completed |
NCT01212380 -
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
|
Phase 1 | |
Completed |
NCT00896792 -
Nurse Practitioner Hospice Program for Patients With Terminal Metastatic Cancer and Their Families or Caregivers
|
Early Phase 1 | |
Recruiting |
NCT03110640 -
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
|
Phase 1 | |
Completed |
NCT01982682 -
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
|
Phase 2 | |
Active, not recruiting |
NCT05147311 -
Positive Psychology Intervention In HSCT
|
N/A | |
Completed |
NCT04172818 -
Feasibility Study of a Diary for Allogenic Hematopoietic Stem Cell Transplantation Patients and Families
|
N/A | |
Completed |
NCT00670917 -
Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy
|
N/A | |
Withdrawn |
NCT00899808 -
Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer
|
N/A | |
Recruiting |
NCT02081937 -
CART-19 Immunotherapy in Mantle Cell Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02194413 -
Effects of Healing Touch on Patients Undergoing Hematopoietic Stem Cell Transplant
|
N/A | |
Completed |
NCT01029366 -
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
|
Phase 1 | |
Terminated |
NCT03121534 -
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
|
Phase 2 | |
Withdrawn |
NCT01620229 -
Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01866969 -
Quality of Life in Caregivers of Hospitalized Older Patients With Cancer
|
N/A | |
Completed |
NCT00068315 -
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 |